Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: Rationale and design

International Journal of Stroke

Volumn 8, Issue 6, 2013, Pages 479-483

  Johnston, S Claiborne ^a   Easton, J Donald ^a   Farrant, Mary ^a   Barsan, William ^b   Battenhouse, Holly ^c   Conwit, Robin ^d   Dillon, Catherine ^c   Elm, Jordan ^d   Lindblad, Anne ^e   Morgenstern, Lewis ^b   Poisson, Sharon N ^f   Palesch, Yuko ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d National Institute of Neurological Disorders   (United States)

^e EMMES CORPORATION   (United States)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Aspirin; Clinical trial; Clopidogrel; Minor stroke; Stroke prevention; TIA

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PLACEBO;

ADULT; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STUDY DESIGN; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

ASPIRIN; CLINICAL TRIAL; CLOPIDOGREL; MINOR STROKE; STROKE PREVENTION; TIA;

ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; BLOOD PLATELETS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RESEARCH DESIGN; STROKE; TICLOPIDINE; YOUNG ADULT;

EID: 84881488396     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/ijs.12129     Document Type: Article

References (27)

1. Johnston SC, Fayad PB, Gorelick PB etal. Prevalence and knowledge of transient ischemic attack among US adults. Neurology 2003; 60:1429-1434.
2. Kleindorfer D, Panagos P, Pancioli A etal. Incidence and short-term prognosis of transient ischemic attack in a population-based study. Stroke 2005; 36:720-723.
3. Writing Group Members, Roger VL, Go AS etal. Heart disease and stroke statistics-2012 update. Circulation 2012; 125:e2-e220.
4. Alexandrov AV, Felberg RA, Demchuk AM etal. Deterioration following spontaneous improvement: sonographic findings in patients with acutely resolving symptoms of cerebral ischemia. Stroke 2000; 31:915-919.
5. Aslanyan S, Weir CJ, Johnston CS, Krams M, Grieve AP, Lees KR. The association of post-stroke neurological improvement with risk of subsequent deterioration due to stroke events. Eur J Neurol 2007; 14:1-6.
6. Aslanyan S, Weir CJ, Johnston SC, Lees KR. Poststroke neurological improvement within 7 days is associated with subsequent deterioration. Stroke 2004; 35:2165-2170.
7. Grotta JC, Welch KM, Fagan SC etal. Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial. Stroke 2001; 32:661-668.
8. Howard G, Toole JF, Frye-Pierson J, Hinshelwood LC. Factors influencing the survival of 451 transient ischemic attack patients. Stroke 1987; 18:552-557.
9. Johnston SC, Leira EC, Hansen MD, Adams HP, Jr. Early recovery after cerebral ischemia: risk of subsequent neurological deterioration. Ann Neurol 2003; 54:439-444.
10. Johnston SC, Easton JD. Are patients with acutely recovered cerebral ischemia more unstable? Stroke 2003; 34:2446-2450.
11. Giles MF, Rothwell PM. Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol 2007; 6:1063-1072.
12. Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000; 284:2901-2906.
13. Rothwell PM, Warlow CP. Timing of TIAs preceding stroke: time window for prevention is very short. Neurology 2005; 64:817-820.
14. Antman EM, Wiviott SD, Murphy SA etal. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008; 51:2028-2033.
15. Bhatt DL, Flather MD, Hacke W etal. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49:1982-1988.
16. Diener HC, Bogousslavsky J, Brass LM etal. Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischaemic Attack or Ischaemic Stroke (MATCH): study design and baseline data. Cerebrovasc Dis 2004; 17:253-261.
17. Morrow DA, Braunwald E, Bonaca MP etal. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366:1404-1413.
18. Sacco RL, Diener HC, Yusuf S etal. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359:1238-1251.
19. The ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360:2066-2078.
20. The SPS3 Investigators. Secondary Prevention of Small Subcortical Strokes Trial (SPS3). ClinicalTrials.gov Identifier: NCT00059306; 2011.
21. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM. Fast Assessment of Stroke and Transient Ischaemic Attack to Prevent Early Recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007; 6:961-969.
22. Wang Y, Johnston SC. Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event. Am Heart J 2010; 160:380-386. e1.
23. Johnston SC, Rothwell PM, Nguyen-Huynh MN etal. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 2007; 369:283-292.
24. Lyden P, Brott T, Tilley B etal. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke 1994; 25:2220-2226.
25. Easton JD, Saver JL, Albers GW etal. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke 2009; 40:2276-2293.
26. Coutts SB, Hill MD, Campos CR etal. Recurrent events in transient ischemic attack and minor stroke: what events are happening and to which patients? Stroke 2008; 39:2461-2466.
27. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3:692-694.